Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases

被引：8
|
作者：
Tung, Nadine M.
Im, Seock-Ah
Senkus-Konefka, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Li, Wei
Armstrong, Anne Caroline
Conte, Pier Franco
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Robson, Mark E.
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Dana Farber Harvard Canc Ctr, Boston, MA USA
[3] Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea
[4] Med Univ Gdansk, Gdansk, Poland
[5] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[6] Peking Union Med Coll CAMS & PUMC, Beijing, Peoples R China
[7] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA
[8] Natl Hosp Org, Osaka, Japan
[9] Jilin Univ, Hosp 1, Changchun, Peoples R China
[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[11] Univ Padua, Padua, Italy
[12] Ist Oncol Veneto IRCCS, Padua, Italy
[13] AstraZeneca, Gaithersburg, MD USA
[14] AstraZeneca, Macclesfield, Cheshire, England
[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
    Domchek, Susan M.
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Armstrong, Anne
    Conte, Pierfranco
    Bannister, Wendy
    Goessl, Carsten
    Runswick, Sarah
    Goel, Saurabh
    Tung, Nadine
    CANCER RESEARCH, 2018, 78 (04)
  • [2] OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
    Robson, M. E.
    Tung, N.
    Conte, P.
    Im, S-A
    Senkus, E.
    Xu, B.
    Masuda, N.
    Delaloge, S.
    Li, W.
    Armstrong, A.
    Wu, W.
    Goessl, C.
    Runswick, S.
    Domchek, S. M.
    ANNALS OF ONCOLOGY, 2019, 30 (04) : 558 - 566
  • [3] OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten
    Runswick, Sarah
    Conte, Pierfranco
    CANCER RESEARCH, 2018, 78 (13)
  • [4] OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Bannister, Wendy
    Goessl, Carsten
    Allen, Allison
    Conte, Pierfranco
    CANCER RESEARCH, 2020, 80 (04)
  • [5] OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Tung, Nadine
    Armstrong, Anne
    Dymond, Mike
    Fielding, Anitra
    Allen, Allison
    Conte, Pierfranco
    EUROPEAN JOURNAL OF CANCER, 2023, 184 : 39 - 47
  • [6] Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
    Senkus-Konefka, E.
    Domchek, S. M.
    Im, S. A.
    Xu, B.
    Armstrong, A.
    Masuda, N.
    Delaloge, S.
    Li, W.
    Tung, N.
    Conte, P.
    Wu, W.
    Goessl, C.
    Runswick, S.
    Robson, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S19 - S20
  • [7] OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice
    Delaloge, S.
    Conte, P. F.
    Im, S-A.
    Senkus-Konefka, E.
    Xu, B.
    Domchek, S. M.
    Masuda, N.
    Li, W.
    Tung, N.
    Armstrong, A.
    Wu, W.
    Goessl, C.
    Runswick, S.
    Robson, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
    Robson, Mark
    Ruddy, Kathryn J.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Delaloge, Suzette
    Bannister, Wendy
    Goessl, Carsten
    Degboe, Arnold
    Hettle, Robert
    Conte, Pierfranco
    EUROPEAN JOURNAL OF CANCER, 2019, 120 : 20 - 30
  • [9] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [10] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345